Published Date: 18 Nov 2024
Patients with complete response can have long treatment-free interval, study suggests
Read Full NewsResearchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive ...
The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
1.
Distinct results for patients with positive and negative pancreatic cancer who are treated with systemic therapy, chemotherapy, and radiation.
2.
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study
3.
Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests
4.
Five-year survival in patients with unresectable hepatocellular carcinoma sets milestone
5.
Study finds primary-care doctors often overlook prostate cancer risk in Black men
1.
The Lung Cancer Shift: From Reactive Treatment to Proactive Precision Medicine
2.
Cancer Rates on the Rise: What Can We Do to Stop It?
3.
Gut microbiota in curing cancer
4.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
5.
Unlocking the Potential of Elotuzumab: A Promising New Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation